Logo-jrip
Submitted: 29 Aug 2022
Accepted: 20 Jan 2023
ePublished: 28 Jan 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2023;12(4): e32130.
doi: 10.34172/jrip.2023.32130

Scopus ID: 85174714876
  Abstract View: 806
  PDF Download: 454

Original

COVID-19 outcomes in kidney transplant recipients receiving a combination of sofosbuvir-daclatasvir treatment; a single-center study

Fatemeh Yaghoubi 1* ORCID logo, Farnaz Tavakoli 1 ORCID logo, Davood Dalil 2 ORCID logo, Marjan Akhavan 1 ORCID logo, Samira Abbasloo 1 ORCID logo

1 Nephrology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran
*Corresponding Author: Fatemeh Yaghoubi, Email: sf-yaghoobi@sina.tums.ac.ir

Abstract

Introduction: In the coronavirus disease 2019 (COVID-19) era, kidney transplantation recipients (KTRs) are at high risk due to using immunosuppressive drugs. Considering the lack of definitive cure for COVID-19, repurposing existing pharmaceuticals is a way to find an immediate medication.

Objectives: This study aimed to evaluate the COVID-19 outcomes in KTRs, receiving combination of sofosbuvir and daclatasvir (SOF-DAC) treatment.

Patients and Methods: This research was an observational study of 12 adult kidney transplant recipients with COVID-19, admitted to Shariati hospital, Tehran, Iran (October to December 2020). All the patients received a once-daily combination pill of SOF-DAC at a dose of 400/60 mg for 10 days.

Results: Around October to December 2020, 12 adult KTR patients were recruited; four patients (33.3%) died and eight patients survived (66.7%). Acute kidney injury (AKI) secondary to COVID-19 was seen in 11 patients of the study population (91.7%), including four dead cases. Two of the three patients who underwent dialysis due to kidney complications, died. The laboratory results showed that the mean level of each parameter white blood cells (WBC), international normalized ratio (INR), C-reactive protein (CRP), ferritin, D-dimer on the last day of hospital stay was significantly different between two groups of survived and dead patients at a 95% confidence level (P<0.05).

Conclusion: Sofosbuvir combined with DAC for treatment of KTRs with COVID-19 infection reduced the mortality rate. Further, this medication was safe. Patients tolerated it well, and no serious adverse effects were observed. Larger studies are needed to validate these results.


Implication for health policy/practice/research/medical education:

This study aimed to evaluate the COVID-19 outcomes in 12 hospitalized adult kidney transplant recipients, receiving the combination of sofosbuvir and daclatasvir (SOF-DAC) treatment. The treatment was safe and tolerated well. No serious adverse effects were observed. The mortality rate was reduced.

Please cite this paper as: Yaghoubi F, Tavakoli F, Dalil D, Akhavan M, Abbasloo S. COVID-19 outcomes in kidney transplant recipients receiving a combination of sofosbuvir-daclatasvir treatment; a single-center study. J Renal Inj Prev. 2023; 12(4): e32130. doi: 10.34172/jrip.2023.32130.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 807

Your browser does not support the canvas element.


PDF Download: 454

Your browser does not support the canvas element.